BDBM387820 2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2-yl)-N-(cyclopropylmethyl)acetamide::US10294226, Compound Ex. 3::US10487083, Example 3::US10981911, Example 3::US11059823, Example 3

SMILES O=C(Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1)NCC1CC1

InChI Key

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 387820   

TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  11.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  82.8nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  11.6nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2 [532-1132](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  6.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  82.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  11.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1 [574-1154](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2 [532-1132](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  6.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3 [512-1124](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  82.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182,C936A,C1142A](Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  11.6nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  6.20nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  82.8nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387820(2-(1-((1r,4r)-4-(Cyanomethyl)cyclohexyl)-1,6-dihyd...)
Affinity DataIC50:  6.20nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent